SNDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Syndax Pharmaceuticals Inc (SNDX) is not a strong buy for a beginner, long-term investor at this moment. While the technical indicators show a neutral to slightly bullish trend, the lack of significant positive catalysts, weak financial performance, and absence of recent news or influential activity make it less compelling as a long-term investment. Holding for now is the better approach.
The stock shows a slightly bullish trend with MACD histogram above zero, bullish moving averages (SMA_5 > SMA_20 > SMA_200), and RSI in the neutral zone at 51.898. Key resistance levels are R1: 21.76 and R2: 22.234, while support levels are S1: 20.224 and S2: 19.75. Pre-market price is $21.15, up 0.05%.
Analysts have raised price targets recently (e.g., Barclays raised to $35 from $22, BofA raised to $28 from $27), and the stock has a 30% chance to gain 3.04% in the next week based on historical patterns.
No recent news or significant insider/hedge fund trading activity. Financial performance is weak with declining net income (-27.83% YoY), EPS (-28.57% YoY), and gross margin (-4.58% YoY).
In Q3 2025, revenue increased significantly by 266.97% YoY to $45.87M, but net income dropped to -$60.72M (-27.83% YoY), EPS fell to -0.7 (-28.57% YoY), and gross margin declined to 95.42% (-4.58% YoY).
Analysts maintain a positive outlook with raised price targets (e.g., Barclays to $35, BofA to $28) and Buy/Overweight ratings. However, upcoming Q4 earnings may not have a significant impact.
